Browse EGFR

Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Endoplasmic reticulum membrane Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome Endosome membrane. Nucleus Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055). ; SUBCELLULAR LOCATION: Isoform 2: Secreted.
Domain PF00757 Furin-like cysteine rich region
PF14843 Growth factor receptor domain IV
PF07714 Protein tyrosine kinase
PF01030 Receptor L domain
Function

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Plays a role in enhancing learning and memory performance (By similarity). ; FUNCTION: Isoform 2 may act as an antagonist of EGF action.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000186 activation of MAPKK activity
GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001558 regulation of cell growth
GO:0001654 eye development
GO:0001701 in utero embryonic development
GO:0001889 liver development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001894 tissue homeostasis
GO:0001942 hair follicle development
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006282 regulation of DNA repair
GO:0006417 regulation of translation
GO:0006606 protein import into nucleus
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0006801 superoxide metabolic process
GO:0006809 nitric oxide biosynthetic process
GO:0006913 nucleocytoplasmic transport
GO:0006970 response to osmotic stress
GO:0006979 response to oxidative stress
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007202 activation of phospholipase C activity
GO:0007270 neuron-neuron synaptic transmission
GO:0007346 regulation of mitotic cell cycle
GO:0007423 sensory organ development
GO:0007431 salivary gland development
GO:0007435 salivary gland morphogenesis
GO:0007494 midgut development
GO:0007584 response to nutrient
GO:0007611 learning or memory
GO:0007623 circadian rhythm
GO:0008015 blood circulation
GO:0008544 epidermis development
GO:0009306 protein secretion
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009612 response to mechanical stimulus
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009914 hormone transport
GO:0009991 response to extracellular stimulus
GO:0010001 glial cell differentiation
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010608 posttranscriptional regulation of gene expression
GO:0010817 regulation of hormone levels
GO:0010863 positive regulation of phospholipase C activity
GO:0010960 magnesium ion homeostasis
GO:0014002 astrocyte development
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0015833 peptide transport
GO:0016049 cell growth
GO:0016101 diterpenoid metabolic process
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0017038 protein import
GO:0017148 negative regulation of translation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019229 regulation of vasoconstriction
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021782 glial cell development
GO:0021795 cerebral cortex cell migration
GO:0021885 forebrain cell migration
GO:0021987 cerebral cortex development
GO:0022029 telencephalon cell migration
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0022612 gland morphogenesis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030258 lipid modification
GO:0030307 positive regulation of cell growth
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030335 positive regulation of cell migration
GO:0030900 forebrain development
GO:0031047 gene silencing by RNA
GO:0031050 dsRNA fragmentation
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031349 positive regulation of defense response
GO:0031657 regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0031659 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0031667 response to nutrient levels
GO:0031960 response to corticosteroid
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032355 response to estradiol
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032429 regulation of phospholipase A2 activity
GO:0032430 positive regulation of phospholipase A2 activity
GO:0032431 activation of phospholipase A2 activity
GO:0032768 regulation of monooxygenase activity
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032928 regulation of superoxide anion generation
GO:0032930 positive regulation of superoxide anion generation
GO:0033002 muscle cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033273 response to vitamin
GO:0033590 response to cobalamin
GO:0033594 response to hydroxyisoflavone
GO:0033674 positive regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034105 positive regulation of tissue remodeling
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034504 protein localization to nucleus
GO:0035150 regulation of tube size
GO:0035194 posttranscriptional gene silencing by RNA
GO:0035195 gene silencing by miRNA
GO:0035196 production of miRNAs involved in gene silencing by miRNA
GO:0035239 tube morphogenesis
GO:0035249 synaptic transmission, glutamatergic
GO:0035272 exocrine system development
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035413 positive regulation of catenin import into nucleus
GO:0035690 cellular response to drug
GO:0038127 ERBB signaling pathway
GO:0038128 ERBB2 signaling pathway
GO:0040017 positive regulation of locomotion
GO:0040029 regulation of gene expression, epigenetic
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:0042063 gliogenesis
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042303 molting cycle
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042310 vasoconstriction
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042493 response to drug
GO:0042554 superoxide anion generation
GO:0042633 hair cycle
GO:0042698 ovulation cycle
GO:0042743 hydrogen peroxide metabolic process
GO:0042886 amide transport
GO:0043006 activation of phospholipase A2 activity by calcium-mediated signaling
GO:0043010 camera-type eye development
GO:0043200 response to amino acid
GO:0043331 response to dsRNA
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043586 tongue development
GO:0043588 skin development
GO:0044057 regulation of system process
GO:0044708 single-organism behavior
GO:0044744 protein targeting to nucleus
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045124 regulation of bone resorption
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045453 bone resorption
GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045739 positive regulation of DNA repair
GO:0045740 positive regulation of DNA replication
GO:0045780 positive regulation of bone resorption
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045860 positive regulation of protein kinase activity
GO:0045907 positive regulation of vasoconstriction
GO:0045909 positive regulation of vasodilation
GO:0045927 positive regulation of growth
GO:0045930 negative regulation of mitotic cell cycle
GO:0046209 nitric oxide metabolic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046777 protein autophosphorylation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046834 lipid phosphorylation
GO:0046849 bone remodeling
GO:0046850 regulation of bone remodeling
GO:0046852 positive regulation of bone remodeling
GO:0046854 phosphatidylinositol phosphorylation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048143 astrocyte activation
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048511 rhythmic process
GO:0048545 response to steroid hormone
GO:0048546 digestive tract morphogenesis
GO:0048565 digestive tract development
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048708 astrocyte differentiation
GO:0048732 gland development
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050880 regulation of blood vessel size
GO:0050890 cognition
GO:0050999 regulation of nitric-oxide synthase activity
GO:0051047 positive regulation of secretion
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051205 protein insertion into membrane
GO:0051222 positive regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051341 regulation of oxidoreductase activity
GO:0051384 response to glucocorticoid
GO:0051592 response to calcium ion
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0051966 regulation of synaptic transmission, glutamatergic
GO:0051968 positive regulation of synaptic transmission, glutamatergic
GO:0055123 digestive system development
GO:0060147 regulation of posttranscriptional gene silencing
GO:0060148 positive regulation of posttranscriptional gene silencing
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060249 anatomical structure homeostasis
GO:0060541 respiratory system development
GO:0060571 morphogenesis of an epithelial fold
GO:0060964 regulation of gene silencing by miRNA
GO:0060966 regulation of gene silencing by RNA
GO:0060968 regulation of gene silencing
GO:0061008 hepaticobiliary system development
GO:0061029 eyelid development in camera-type eye
GO:0061458 reproductive system development
GO:0070141 response to UV-A
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070459 prolactin secretion
GO:0070849 response to epidermal growth factor
GO:0070918 production of small RNA involved in gene silencing by RNA
GO:0070920 regulation of production of small RNA involved in gene silencing by RNA
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071359 cellular response to dsRNA
GO:0071364 cellular response to epidermal growth factor stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071384 cellular response to corticosteroid stimulus
GO:0071385 cellular response to glucocorticoid stimulus
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0071548 response to dexamethasone
GO:0071549 cellular response to dexamethasone stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072507 divalent inorganic cation homeostasis
GO:0072593 reactive oxygen species metabolic process
GO:0072657 protein localization to membrane
GO:0080184 response to phenylpropanoid
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090150 establishment of protein localization to membrane
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0090316 positive regulation of intracellular protein transport
GO:0090322 regulation of superoxide metabolic process
GO:0097421 liver regeneration
GO:0098773 skin epidermis development
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1900274 regulation of phospholipase C activity
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1902593 single-organism nuclear import
GO:1902722 positive regulation of prolactin secretion
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1903533 regulation of protein targeting
GO:1903798 regulation of production of miRNAs involved in gene silencing by miRNA
GO:1903800 positive regulation of production of miRNAs involved in gene silencing by miRNA
GO:1903829 positive regulation of cellular protein localization
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904031 positive regulation of cyclin-dependent protein kinase activity
GO:1904407 positive regulation of nitric oxide metabolic process
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:1990267 response to transition metal nanoparticle
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000147 positive regulation of cell motility
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000637 positive regulation of gene silencing by miRNA
GO:2001020 regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0001948 glycoprotein binding
GO:0003682 chromatin binding
GO:0003779 actin binding
GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004709 MAP kinase kinase kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0004716 receptor signaling protein tyrosine kinase activity
GO:0005006 epidermal growth factor-activated receptor activity
GO:0005057 receptor signaling protein activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005178 integrin binding
GO:0005516 calmodulin binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0030235 nitric-oxide synthase regulator activity
GO:0031625 ubiquitin protein ligase binding
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0042562 hormone binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0045296 cadherin binding
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0046982 protein heterodimerization activity
GO:0048408 epidermal growth factor binding
GO:0050839 cell adhesion molecule binding
GO:0051015 actin filament binding
GO:0052813 phosphatidylinositol bisphosphate kinase activity
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005635 nuclear envelope
GO:0005769 early endosome
GO:0005770 late endosome
GO:0005771 multivesicular body
GO:0005775 vacuolar lumen
GO:0005905 clathrin-coated pit
GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0010008 endosome membrane
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0030055 cell-substrate junction
GO:0030117 membrane coat
GO:0030118 clathrin coat
GO:0030119 AP-type membrane coat adaptor complex
GO:0030120 vesicle coat
GO:0030122 AP-2 adaptor complex
GO:0030125 clathrin vesicle coat
GO:0030128 clathrin coat of endocytic vesicle
GO:0030131 clathrin adaptor complex
GO:0030132 clathrin coat of coated pit
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0031901 early endosome membrane
GO:0031965 nuclear membrane
GO:0031983 vesicle lumen
GO:0043235 receptor complex
GO:0044440 endosomal part
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0045334 clathrin-coated endocytic vesicle
GO:0048475 coated membrane
GO:0070435 Shc-EGFR complex
GO:0097487 multivesicular body, internal vesicle
GO:0097489 multivesicular body, internal vesicle lumen
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04020 Calcium signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04320 Dorso-ventral axis formation
hsa04510 Focal adhesion
hsa04520 Adherens junction
hsa04540 Gap junction
hsa04810 Regulation of actin cytoskeleton
hsa04912 GnRH signaling pathway
hsa04915 Estrogen signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-5637810: Constitutive Signaling by EGFRvIII
R-HSA-1236382: Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-8863795: Downregulation of ERBB2 signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2179392: EGFR Transactivation by Gastrin
R-HSA-182971: EGFR downregulation
R-HSA-212718: EGFR interacts with phospholipase C-gamma
R-HSA-8847993: ERBB2 Activates PTK6 Signaling
R-HSA-6785631: ERBB2 Regulates Cell Motility
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-1963640: GRB2 events in ERBB2 signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-5638303: Inhibition of Signaling by Overexpressed EGFR
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-373760: L1CAM interactions
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-199991: Membrane Trafficking
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-1963642: PI3K events in ERBB2 signaling
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-1251932: PLCG1 events in ERBB2 signaling
R-HSA-8857538: PTK6 promotes HIF1A stabilization
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-1250196: SHC1 events in ERBB2 signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-445144: Signal transduction by L1
R-HSA-177929: Signaling by EGFR
R-HSA-1643713: Signaling by EGFR in Cancer
R-HSA-5637812: Signaling by EGFRvIII in Cancer
R-HSA-1227986: Signaling by ERBB2
R-HSA-1236394: Signaling by ERBB4
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-5637815: Signaling by Ligand-Responsive EGFR Variants in Cancer
R-HSA-5638302: Signaling by Overexpressed Wild-Type EGFR in Cancer
R-HSA-186797: Signaling by PDGF
R-HSA-8848021: Signaling by PTK6
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EGFR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EGFR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26759242Triple-Negative Breast CarcinomaInhibit immunity (T cell function)Furthermore, we showed that one of these intermediates, fructose 1,6 bisphosphate (F1,6BP), directly binds to and enhances the activity of the EGFR, thereby increasing lactate excretion, which leads to inhibition of local cytotoxic T-cell activity.
26676749Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function)Interferon gamma (IFNγ) and the epidermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to transmit tumor cell-mediated extrinsic or intrinsic signals, respectively. Collectively, our findings suggest a novel role for JAK2/STAT1 in EGFR-mediated immune evasion, and therapies targeting this signaling axis may be beneficial to block PD-L1 upregulation found in a large subset of HNC tumors.
26055519Cervical CarcinomaInhibit immunityThus, our study reveals an EGFR-IFRD1-mediated viral immune evasion mechanism, which can also be exploited by cancer cells.
25972070Head and Neck Squamous Cell CarcinomaInhibit immunityEGFR induces HLA downregulation through SHP-2/STAT1 suppression. Abrogating EGFR-induced immune escape mechanisms and restoring STAT1 signaling to reverse HLA downregulation using cetuximab should be combined with strategies to enhance adaptive cellular immunity.
25658629Non-Small Cell Lung CarcinomaInhibit immunity (T cell function)EGFR activation upregulated PD-L1 through p-ERK1/2/p-c-Jun but not through p-AKT/p-S6 pathway. PD-L1 mediated by EGFR activation could induce the apoptosis of T cells through PD-L1/PD-1 axis in tumor cells and peripheral blood mononuclear cells coculture system.
27765535Non-Small Cell Lung CarcinomaPromote immunity; Essential for immunotherapyIn the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03). In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel.
24570975GlioblastomaInhibit immunity (T cell function); immunotherapy targetHere, we show that a bscAb targeting the tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, redirects human CD4(+)CD25(+)FoxP3(+) T(regs) to kill glioblastoma (GBM) cells.
24550086Hepatocellular carcinomaInhibit immunity; immunotherapy targetAs tumour regression in our model resembles the targeted inhibition of EGFR in cancer therapy, our observations may provide molecular insights into the targeted inhibition and highlight the importance of immune response in tumour regression.
16397041Lung carcinoma; Pancreatic carcinoma; Prostate carcinoma; Malignant Brain Neoplasm; MelanomaInhibit immunityAnti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Specific cytolytic activity of ATC armed with anti-CD3 x anti-EGFR (EGFRBi) against EGFR-expressing cancer cells derived from lung, pancreas, colon, prostate, brain, skin, or EGFR-negative breast cancer cells was evaluated in (51)Cr release assays.
27402485Pancreatic carcinomaInhibit immunityOur results show that myeloid cells support immune evasion in pancreatic cancer through EGFR/MAPK-dependent regulation of PD-L1 expression on tumour cells.
23100515Non-small-cell lung carcinomaInhibit immunityA clinical study in non-small cell lung cancer patients demonstrated a positive correlation between EGFR expression levels and the therapeutic efficacy of the EGFR mAb cetuximab. Interestingly, Ab-dependent cell-mediated cytotoxicity (ADCC) by NK cells, monocytes, or polymorphonuclear cells as well as complement-dependent cytotoxicity positively correlated with the number of EGFR molecules. In comparison with ADCC by mononuclear cells, polymorphonuclear cell-mediated ADCC and complement-dependent cytotoxicity required higher EGFR expression levels and higher mAb concentrations to trigger significant tumor cell killing.
27496866Head and Neck CarcinomaInhibit immunity (NK cell function); immunotherapy targetCetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is important for inducing antitumor cellular immunity. Cetuximab-activated NK cells upregulate the costimulatory receptor CD137 (4-1BB), which, when triggered by agonistic mAb urelumab, might enhance NK-cell functions, to promote T-cell-based immunity.
22315057Colorectal CarcinomaInhibit immunityPre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor.
18025475Actinic (Solar) Keratosis; Skin Basal Cell Carcinoma; Squamous Cell CarcinomaInhibit immunity (T cell function)Here we demonstrate that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways. Compared with healthy skin, CCL27 mRNA and protein expression was progressively lost in transformed keratinocytes of actinic keratoses and basal and squamous cell carcinomas.
17363548GliomaInhibit immunityWe examined the efficacy of two EGFR-specific mAbs (mAbs 806 and 528) against U87MG-derived glioma xenografts expressing EGFR variants. Whereas mAb 806 displayed antitumor activity against NR6 xenografts, mAb 528 therapy was ineffective, suggesting that mAb 528 mediates its antitumor activity by disrupting interactions between the de2-7 and wild-type EGFR. Finally, genetic disruption of Src in U87MG xenografts expressing the de2-7 EGFR dramatically enhanced mAb 806 efficacy.
17332301Lung CarcinomaInhibit immunityA logarithmic correlation was observed between the number of EGFRs and ADCC activity. In addition, ADCC activity was enhanced by interleukin-2 mainly through activation of NK cells and was less susceptible to immunosuppression by chemotherapy than NK activity in lung cancer patients.
28387924Lung CarcinomaPromote immunity (infiltration)We have investigated lung cancer specimens for somatic mutations in a targeted panel of 612 human genes, the majority being protein kinases. There was a significant inverse correlation between the number of infiltrating stromal CD8+ lymphocytes and the presence of EGFR mutations.
29672836Colorectal Carcinoma; urothelial carcinoma; urachal adenocarcinomasInhibit immunity (T cell function); immunotherapy targetEGFR Gene amplifications were found in EGFR (5%), ERBB2 (2%), and MET (2%).
29644393carcinoma in situInhibit immunity immunotherapy targetIntravesical instillation of 213Bi-anti-EGFR monoclonal antibody was well tolerated and showed therapeutic efficacy.
29628320lung adenocarcinomaInhibit immunity immunotherapy targetWe collected 105 surgically resected (50 EGFR mutated and 55 EGFR wild-type), treatment-na?ve lung adenocarcinoma tissues with clinical data to investigate the landscape and compartmentalization of tumor-infiltrating immune cells with respect to EGFR status by immunohistochemistry.
29596910Recurrent Non-Small Cell Lung CarcinomaInhibit immunity immunotherapy targetFurthermore, treatment of NSCLC cell lines that harbor such driver oncogenes with corresponding EGFR or ALK tyrosine kinase inhibitors or depletion of EGFR or ALK by small interfering RNA transfection suppressed expression of PD-L2, demonstrating that activating EGFR mutations or echinoderm microtubule associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene (ALK) fusion intrinsically induce PD-L2 expression.
24045666Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function); immunotherapy targetEpidermal growth factor receptor (EGFR)-targeted therapy is an attractive strategy alternative to conventional cancer treatments for HNSCC, but its efficacy remains controversial. The results provide support for a novel strategy to treat HNSCC by combining EGFR-targeted therapy with T-cell-based immunotherapy. Among several predicted peptide epitopes, EGFR875-889 elicited CD4 T-cell responses that were restricted by HLA-DR4, DR15, or DR53 molecules, indicating that the peptide functions as a promiscuous T-cell epitope. The peptide-reactive T cells responded to autologous dendritic cells loaded with EGFR-expressing tumour cell lysates, indicating that these epitopes are naturally processed.
29293164Colorectal CancinomaInhibit immunity (NK cell function); immunotherapy targetIn Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status. These data open perspectives for combined NK-based immunotherapy with anti-epidermal growth factor receptor antibodies in a cohort of mCRC patients with a poor prognosis refractory to conventional therapies.
18593896Colon Cacinoma; Head and Neck CarcinomaInhibit immunityTherapeutic monoclonal antibodies against the epidermal growth factor receptor (EGFR) have advanced the treatment of colon and head and neck cancer, and show great promise for the development of treatments for other solid cancers.
18539480Malignant GliomaInhibit immunityTumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
28062695Squamous Cell Carcinoma; Colon CarcinomaInhibit immunity; Candidate for immunotherapy targetMonoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. In this study we show that selective enhancement of C1q binding via avidity modulation is superior to the unattended increase in C1q binding via affinity approaches, particularly for target cells with reduced EGFR expression levels. Improving Fc:Fc interactions of Ag-bound IgG therefore represents a highly promising and novel approach for potentiating the anti-tumor activity of therapeutic mAb against EGFR and potentially other tumor targets.
24078774Lung NeoplasmInhibit immunityWe observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer. Expression of mutant EGFR in bronchial epithelial cells induced PD-L1, and PD-L1 expression was reduced by EGFR inhibitors in non-small cell lung cancer cell lines with activated EGFR. These data suggest that oncogenic EGFR signaling remodels the tumor microenvironment to trigger immune escape and mechanistically link treatment response to PD-1 inhibition. We show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines.
22090361OsteosarcomaInhibit immunity (T cell function)Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. In the presence of cetuximab, the cytolytic activity of resting NK cells against all EGFR-expressing sarcoma cells was substantially increased and comparable with that of IL-15-activated NK cells.
16288119Squamous Cell CarcinomaInhibit immunityIn both cellular cytotoxicity assays, the mimotope-induced antibodies exhibited specific lysis of more than 50%. The induced antibodies caused internalization of the receptor from the cell surface into endocytic vesicles and inhibited growth of EGFR-expressing cells to a similar extent as cetuximab [67% (95% confidence interval {CI} = 55% to 79%) and 69% (95% CI = 55% to 84%), respectively].
16234565Ovarian CarcinomaInhibit immunityWe tested a combination regimen consisting of C225, a monoclonal antibody that inhibits the receptor tyrosine kinase activity of EGFR, and benzoporphyrin derivative monoacid A (BPD)-based PDT in a mouse model of human ovarian cancer.
16203806Squamous Cell CarcinomaResistant to immunotherapyEnhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. The combination of 0.4 mg AG1478 with a single dose of 25 microCi 90Y-CHX-A''-DTPA-hu3S193 resulted in a significant enhancement of efficacy compared with either agent alone.
21984704Lung CarcinomaInhibit immunityThis is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.
16841332Lung CarcinomaInhibit immunityNoteworthy, vaccination of mice with mEGFR-ECD/VSSP stimulated a potent antimetastatic effect in the EGFR+ Lewis lung carcinoma model, while reproduction-associated side effects were absent. Curiously, mice immunized with the human EGFR-ECD (Her1-ECD) in VSSP though induced highly specific IgG antibodies with strong in vitro cytotoxic effect over EGFR+ human cell lines, showed low cross-reactivity with the mEGFR-ECD. These results further encouraged the development of the Her1-ECD/VSSP vaccine project for patients with EGFR+ tumors.
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EGFR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EGFR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7230.145
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4940.0784
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1530.828
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2540.498
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1910.941
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3370.917
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2940.622
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1180.25
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7080.526
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1930.904
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4120.864
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3640.0229
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EGFR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414014.3-14.31
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.86.880.247
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EGFR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EGFR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EGFR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EGFR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EGFR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EGFR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEGFR
Nameepidermal growth factor receptor
Aliases ERBB1; erythroblastic leukemia viral (v-erb-b) oncogene homolog (avian); erb-b2 receptor tyrosine kinase 1; ......
Chromosomal Location7p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EGFR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting EGFR.
ID Name Drug Type Targets #Targets
DB00002CetuximabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00072TrastuzumabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......13
DB00281LidocaineSmall MoleculeEGFR, ORM1, ORM2, SCN10A, SCN4A, SCN5A, SCN9A7
DB00317GefitinibSmall MoleculeEGFR1
DB00530ErlotinibSmall MoleculeEGFR, NR1I22
DB01259LapatinibSmall MoleculeEGFR, ERBB22
DB01269PanitumumabBiotechEGFR1
DB03496AlvocidibSmall MoleculeCDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGB, PYGL, ......12
DB04988IGN311BiotechEGFR, ERBB22
DB05101MatuzumabBiotechEGFR1
DB05294VandetanibSmall MoleculeEGFR, PTK6, RET, TEK, VEGFA5
DB05374RindopepimutSmall MoleculeEGFR1
DB05424CanertinibSmall MoleculeEGFR1
DB05524PelitinibSmall MoleculeEGFR1
DB05944VarlitinibSmall MoleculeEGFR, ERBB22
DB06021AV-412Small MoleculeEGFR, ERBB22
DB07602S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINESmall MoleculeEGFR1
DB07662N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDESmall MoleculeEGFR, SRC2
DB08916AfatinibSmall MoleculeEGFR, ERBB2, ERBB43
DB09330OsimertinibSmall MoleculeEGFR1
DB09559NecitumumabBiotechEGFR1
DB11731Depatuxizumab mafodotinSmall MoleculeEGFR, TUBB2
DB11737IcotinibSmall MoleculeEGFR1
DB11828NeratinibSmall MoleculeEGFR1
DB12202ZalutumumabBiotechEGFR1
DB12267BrigatinibSmall MoleculeABL1, ALK, EGFR, ERBB2, ERBB4, FLT3, IGF1R, INSR, MET9
DB13164OlmutinibSmall MoleculeEGFR1